Price
No data yet.
Social Signal Score
Revenue
$1.39B+78.99%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brenton L. Saunders
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 13,000
- Beta
- 0.55
- Country
- CA
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 0.95
Financials
Revenue
$1.39B+79.0%Net Income
$-14.00M-126.4%EBITDA
$184.00M+30.0%Free Cash Flow
$82.00M+124.7%EPS (diluted)
$-0.04-126.0%Shares Outstanding (diluted)
357.10M+2.0%Operating Expenses
$702.00MCash & Debt
$367.00MReturn of Capital
$27.00MRevenue by Segment (annual)
$5.10BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $5.10B | $-360.00M | $-1.02 |
| 2024 | $4.79B | $-317.00M | $-0.90 |
| 2023 | $4.15B | $-260.00M | $-0.74 |
| 2022 | $3.77B | $6.00M | $0.04 |
| 2021 | $3.77B | $182.00M | $0.52 |
| 2020 | $3.41B | $-18.00M | $-0.05 |
| 2019 | $3.78B | $298.00M | $0.85 |
| 2018 | $3.67B | $710.00M | $2.03 |
Valuation
BLCOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60Social Signal Score
Mentions (1)
- Newsmarketbeat.com·6h ago·Negative
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal Bausch + Lomb NYSE: BLCO said it plans to advance a dual-action dry eye treatment into Phase III development after a Phase II study showed statistically significant improvement in corneal staining at day 15, although the trial did not meet its primary endpoint at day 29.
View source ↗
Earnings
Wed, Nov 4(in 2 months)
Consensus estimate $0.21 per share
Typical surprise +4.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$0.16 vs $0.15beat
- Wed, Apr 29$0.08 vs $0.06beat
- Wed, Feb 18$0.32 vs $0.35miss
- Wed, Oct 29$0.18 vs $0.16beat
- Wed, Jul 30$0.07 vs $0.06beat
- Wed, Apr 30$-0.07 vs $0.03miss
Estimates and results for BLCO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BLCO officers and directors.
- Bought
- $1.2m
- Sold
- $1.2m
9 trades
3 trades
- Munsch Fredericksold
- Von Eschenbach Andrew C.sold
- Von Eschenbach Andrew C.sold
- Bailey A Robert Dbought
- Eldessouky Sambought
- Saunders Brent Lbought
- Ross Thomas W. Sr.bought
- Alfonso Eduardobought
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.